1 Day
Source:
مباشر
Jajoom Pharma advances PIF partnership
Jamjoom Pharmaceuticals (Jamjoom Pharma) announced significant developments in its strategic partnership with Livira, a company owned by the Public Investment Fund. The announcement included the signing of a subscription agreement in Biologix, a company specializing in the manufacturing and marketing of vaccines and biosimilar products within Saudi Arabia. Jamjoom Pharma will subscribe to 4,900 shares with a total nominal value of 490,000 SAR, representing a 49% ownership stake, while Livira owns 51%. The partnership aims to enhance pharmaceutical security and localize vital industries, with a commitment to fund Biologix for five years in accordance with regulatory conditions. This is an important step toward developing the vaccine industry in the Kingdom.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)